This content is only available within our institutional offering.

05 Aug 2024
PANMURE LIBERUM: Hikma Pharmaceuticals: Possible upgrades to guidance will be the main catalyst

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
PANMURE LIBERUM: Hikma Pharmaceuticals: Possible upgrades to guidance will be the main catalyst
Hikma Pharmaceuticals Plc (HIK:LON) | 1,840 -147.2 (-0.4%) | Mkt Cap: 4,083m
- Published:
05 Aug 2024 -
Author:
Julie Simmonds | Seb Jantet -
Pages:
11 -